COMMUNIQUÉS West-GlobeNewswire
-
1104Health and Johns Hopkins Researchers Present Data on Physician Collaboration Across Community and Academic Oncology
27/10/2026 -
AdipoPharma Advances PATAS into Phase 1b Clinical Trial in Patients with Type 2 Diabetes
27/10/2026 -
AscellaHealth Executive Manager Wins 2026 Herizon Award, Recognizing Established Leadership in Team and Department Transformation
27/10/2026 -
National NUCCA doctors highlight importance of spinal health for daily function, better quality of life during World Spine Day observance
27/10/2026 -
Fort Collins Oral and Maxillofacial Surgeon Dr. Daetwyler Provides Free Dental Care in Cripple Creek
27/10/2026 -
Acentra Health Names Mihriban Brickner as Senior Vice President of Operations
27/10/2026 -
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
27/10/2026 -
Coherus to Participate in Upcoming Investor Conferences
27/10/2026 -
Egetis Therapeutics Announces U.S. Launch of EMCITATE® for Patients with MCT8 Deficiency
27/10/2026 -
The Gene Lay Institute of Immunology and Inflammation Expands World-Class Research Leadership, Appointing Four New Members
27/10/2026 -
aTyr Pharma Announces One-for-40 Reverse Stock Split
27/10/2026 -
Emerging Digital Health Companies Choose HealthEx’s Platform and Health Records API to Personalize User Experiences with Clinical Context
27/10/2026 -
Exagen to Announce Third Quarter Financial Results on November 10, 2026
27/10/2026 -
Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments
27/10/2026 -
NorthStar Day Program, First of Its Kind in the Southeast, to Open in Palm Beach Gardens on November 4, 2026
27/10/2026 -
Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease
27/10/2026 -
Syncromune Reports Long-Term Data from Phase 1 Study in Metastatic Prostate Cancer with Investigational SYNC-T Therapy SV-102
27/10/2026 -
Vanquish Brands Announces 2026 Financial Results Estimated to Achieve a 152% 3-Year Annualized Revenue Growth Rate Driven by Its Flagship Brand Pistol and Paris
27/10/2026 -
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
27/10/2026
Pages